{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T14:30:23Z","timestamp":1769005823939,"version":"3.49.0"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,7,28]]},"DOI":"10.7759\/cureus.42626","type":"journal-article","created":{"date-parts":[[2023,7,28]],"date-time":"2023-07-28T21:01:52Z","timestamp":1690578112000},"source":"Crossref","is-referenced-by-count":8,"title":["The Emerging Role of Sigma Receptors in Pain Medicine"],"prefix":"10.7759","author":[{"given":"Joseph","family":"Pergolizzi Jr","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giustino","family":"Varrassi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","article-title":"The effects of morphine- and nalorphine- like drugs in the nondependent and morphine-dependent chronic spinal dog","volume":"197","author":"Martin WR","year":"1976","unstructured":"Martin WR, Eades CG, Thompson JA, Huppler RE, Gilbert PE. The effects of morphine- and nalorphine- like drugs in the nondependent and morphine-dependent chronic spinal dog. J Pharmacol Exp Ther. 1976, 197:517-32.","journal-title":"J Pharmacol Exp Ther"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.35756","article-title":"The sigma enigma: A narrative review of sigma receptors","volume":"15","author":"Pergolizzi J","year":"2023","unstructured":"Pergolizzi J, Varrassi G, Coleman M, Breve F, Christo DK, Christo PJ, Moussa C. The sigma enigma: A narrative review of sigma receptors. Cureus. 2023, 15:e35756. 10.7759\/cureus.35756","journal-title":"Cureus"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.93.15.8072","article-title":"Purification, molecular cloning, and expression of the mammalian sigma1-binding site","volume":"93","author":"Hanner M","year":"1996","unstructured":"Hanner M, Moebius FF, Flandorfer A, Knaus HG, Striessnig J, Kempner E, Glossmann H. Purification, molecular cloning, and expression of the mammalian sigma1-binding site. Proc Natl Acad Sci U S A. 1996, 93:8072-7. 10.1073\/pnas.93.15.8072","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1038\/nature17391","article-title":"Crystal structure of the human \u03c31 receptor","volume":"532","author":"Schmidt HR","year":"2016","unstructured":"Schmidt HR, Zheng S, Gurpinar E, Koehl A, Manglik A, Kruse AC. Crystal structure of the human \u03c31 receptor. Nature. 2016, 532:527-30. 10.1038\/nature17391","journal-title":"Nature"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-319-50174-1_2","article-title":"Structural perspectives on sigma-1 receptor function","volume":"964","author":"Alon A","year":"2017","unstructured":"Alon A, Schmidt H, Zheng S, Kruse AC. Structural perspectives on sigma-1 receptor function. Adv Exp Med Biol. 2017, 964:5-13. 10.1007\/978-3-319-50174-1_2","journal-title":"Adv Exp Med Biol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-04175-x","article-title":"Structures of the \u03c3(2) receptor enable docking for bioactive ligand discovery","volume":"600","author":"Alon A","year":"2021","unstructured":"Alon A, Lyu J, Braz JM, et al.. Structures of the \u03c3(2) receptor enable docking for bioactive ligand discovery. Nature. 2021, 600:759-64. 10.1038\/s41586-021-04175-x","journal-title":"Nature"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.4303\/jdar\/235970","article-title":"Potential molecular mechanisms on the role of the sigma-1 receptor in the action of cocaine and methamphetamine","volume":"5","author":"Yasui Y","year":"2016","unstructured":"Yasui Y, Su TP. Potential molecular mechanisms on the role of the sigma-1 receptor in the action of cocaine and methamphetamine. J Drug Alcohol Res. 2016, 5:235970. 10.4303\/jdar\/235970","journal-title":"J Drug Alcohol Res"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1038\/nature17041","article-title":"Protein misfolding in the endoplasmic reticulum as a conduit to human disease","volume":"529","author":"Wang M","year":"2016","unstructured":"Wang M, Kaufman RJ. Protein misfolding in the endoplasmic reticulum as a conduit to human disease. Nature. 2016, 529:326-35. 10.1038\/nature17041","journal-title":"Nature"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.semcdb.2011.04.002","article-title":"Misfolded protein aggregates: mechanisms, structures and potential for disease transmission","volume":"22","author":"Moreno-Gonzalez I","year":"2011","unstructured":"Moreno-Gonzalez I, Soto C. Misfolded protein aggregates: mechanisms, structures and potential for disease transmission. Semin Cell Dev Biol. 2011, 22:482-7. 10.1016\/j.semcdb.2011.04.002","journal-title":"Semin Cell Dev Biol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2021.113658","article-title":"Bifunctional \u03bc opioid and \u03c3(1) receptor ligands as novel analgesics with reduced side effects","volume":"223","author":"Zhuang T","year":"2021","unstructured":"Zhuang T, Xiong J, Hao S, et al.. Bifunctional \u03bc opioid and \u03c3(1) receptor ligands as novel analgesics with reduced side effects. Eur J Med Chem. 2021, 223:113658. 10.1016\/j.ejmech.2021.113658","journal-title":"Eur J Med Chem"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.9b01256","article-title":"4-Aryl-1-oxa-4,9-diazaspiro[5.5]undecane derivatives as dual \u03bc-opioid receptor agonists and \u03c3(1) receptor antagonists for the treatment of pain","volume":"63","author":"Garc\u00eda M","year":"2020","unstructured":"Garc\u00eda M, Virgili M, Alonso M, et al.. 4-Aryl-1-oxa-4,9-diazaspiro[5.5]undecane derivatives as dual \u03bc-opioid receptor agonists and \u03c3(1) receptor antagonists for the treatment of pain. J Med Chem. 2020, 63:2434-54. 10.1021\/acs.jmedchem.9b01256","journal-title":"J Med Chem"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1080\/00498254.2021.1877850","article-title":"Preliminary in\u00a0vitro approach to evaluate the drug-drug interaction potential of EST73502, a dual \u00b5-opioid receptor partial agonist and \u03c31 receptor antagonist","volume":"51","author":"Ayet E","year":"2021","unstructured":"Ayet E, Yeste S, Reinoso RF, Pretel MJ, Balada A, Serafini MT. Preliminary in\u00a0vitro approach to evaluate the drug-drug interaction potential of EST73502, a dual \u00b5-opioid receptor partial agonist and \u03c31 receptor antagonist. Xenobiotica. 2021, 51:501-12. 10.1080\/00498254.2021.1877850","journal-title":"Xenobiotica"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.0c01127","article-title":"Discovery of EST73502, a dual \u03bc-opioid receptor agonist and \u03c3(1) receptor antagonist clinical candidate for the treatment of pain","volume":"63","author":"Garc\u00eda M","year":"2020","unstructured":"Garc\u00eda M, Virgili M, Alonso M, et al.. Discovery of EST73502, a dual \u03bc-opioid receptor agonist and \u03c3(1) receptor antagonist clinical candidate for the treatment of pain. J Med Chem. 2020, 63:15508-26. 10.1021\/acs.jmedchem.0c01127","journal-title":"J Med Chem"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.4155\/fmc-2018-0072","article-title":"Sigma-2 receptor: past, present and perspectives on multiple therapeutic exploitations","volume":"10","author":"Abate C","year":"2018","unstructured":"Abate C, Niso M, Berardi F. Sigma-2 receptor: past, present and perspectives on multiple therapeutic exploitations. Future Med Chem. 2018, 10:1997-2018. 10.4155\/fmc-2018-0072","journal-title":"Future Med Chem"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.tips.2010.08.007","article-title":"The sigma-1 receptor chaperone as an inter-organelle signaling modulator","volume":"31","author":"Su TP","year":"2010","unstructured":"Su TP, Hayashi T, Maurice T, Buch S, Ruoho AE. The sigma-1 receptor chaperone as an inter-organelle signaling modulator. Trends Pharmacol Sci. 2010, 31:557-66. 10.1016\/j.tips.2010.08.007","journal-title":"Trends Pharmacol Sci"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.103.051284","article-title":"Sigma-1 receptors (sigma(1) binding sites) form raft-like microdomains and target lipid droplets on the endoplasmic reticulum: roles in endoplasmic reticulum lipid compartmentalization and export","volume":"306","author":"Hayashi T","year":"2003","unstructured":"Hayashi T, Su TP. Sigma-1 receptors (sigma(1) binding sites) form raft-like microdomains and target lipid droplets on the endoplasmic reticulum: roles in endoplasmic reticulum lipid compartmentalization and export. J Pharmacol Exp Ther. 2003, 306:718-25. 10.1124\/jpet.103.051284","journal-title":"J Pharmacol Exp Ther"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.109.160960","article-title":"Sigma-1 receptors regulate Bcl-2 expression by reactive oxygen species-dependent transcriptional regulation of nuclear factor kappaB","volume":"332","author":"Meunier J","year":"2010","unstructured":"Meunier J, Hayashi T. Sigma-1 receptors regulate Bcl-2 expression by reactive oxygen species-dependent transcriptional regulation of nuclear factor kappaB. J Pharmacol Exp Ther. 2010, 332:388-97. 10.1124\/jpet.109.160960","journal-title":"J Pharmacol Exp Ther"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1186\/s12929-017-0380-6","article-title":"Roles of sigma-1 receptors on mitochondrial functions relevant to neurodegenerative diseases","volume":"24","author":"Weng TY","year":"2017","unstructured":"Weng TY, Tsai SA, Su TP. Roles of sigma-1 receptors on mitochondrial functions relevant to neurodegenerative diseases. J Biomed Sci. 2017, 24:74. 10.1186\/s12929-017-0380-6","journal-title":"J Biomed Sci"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.genom.7.080505.115737","article-title":"Protein misfolding and human disease","volume":"7","author":"Gregersen N","year":"2006","unstructured":"Gregersen N, Bross P, Vang S, Christensen JH. Protein misfolding and human disease. Annu Rev Genomics Hum Genet. 2006, 7:103-24. 10.1146\/annurev.genom.7.080505.115737","journal-title":"Annu Rev Genomics Hum Genet"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1186\/s40035-023-00358-w","article-title":"A phase 1b randomized clinical trial of CT1812 to measure A\u03b2 oligomer displacement in Alzheimer's disease using an indwelling CSF catheter","volume":"12","author":"LaBarbera KM","year":"2023","unstructured":"LaBarbera KM, Sheline YI, Izzo NJ, et al.. A phase 1b randomized clinical trial of CT1812 to measure A\u03b2 oligomer displacement in Alzheimer's disease using an indwelling CSF catheter. Transl Neurodegener. 2023, 12:24. 10.1186\/s40035-023-00358-w","journal-title":"Transl Neurodegener"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1021\/acsmedchemlett.1c00048","article-title":"Discovery of investigational drug CT1812, an antagonist of the sigma-2 receptor complex for Alzheimer\u2019s disease","volume":"12","author":"Rishton GM","year":"2021","unstructured":"Rishton GM, Look GC, Ni ZJ, et al.. Discovery of investigational drug CT1812, an antagonist of the sigma-2 receptor complex for Alzheimer\u2019s disease. ACS Med Chem Lett. 2021, 12:1389-95. 10.1021\/acsmedchemlett.1c00048","journal-title":"ACS Med Chem Lett"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuro.2010.04.001","article-title":"Microelectrode arrays: a physiologically based neurotoxicity testing platform for the 21st century","volume":"31","author":"Johnstone AF","year":"2010","unstructured":"Johnstone AF, Gross GW, Weiss DG, Schroeder OH, Gramowski A, Shafer TJ. Microelectrode arrays: a physiologically based neurotoxicity testing platform for the 21st century. Neurotoxicology. 2010, 31:331-50. 10.1016\/j.neuro.2010.04.001","journal-title":"Neurotoxicology"},{"key":"ref23","article-title":"Fragile X syndrome","volume":"45","author":"Saldarriaga W","year":"2014","unstructured":"Saldarriaga W, Tassone F, Gonz\u00e1lez-Teshima LY, Forero-Forero JV, Ayala-Zapata S, Hagerman R. Fragile X syndrome. Colomb Med (Cali). 2014, 45:190-8.","journal-title":"Colomb Med (Cali)"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1002\/ajmg.c.30062","article-title":"Fragile X syndrome","volume":"137C","author":"Terracciano A","year":"2005","unstructured":"Terracciano A, Chiurazzi P, Neri G. Fragile X syndrome. Am J Med Genet C Semin Med Genet. 2005, 137C:32-7. 10.1002\/ajmg.c.30062","journal-title":"Am J Med Genet C Semin Med Genet"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1016\/j.cger.2019.08.002","article-title":"Parkinson disease epidemiology, pathology, genetics, and pathophysiology","volume":"36","author":"Simon DK","year":"2020","unstructured":"Simon DK, Tanner CM, Brundin P. Parkinson disease epidemiology, pathology, genetics, and pathophysiology. Clin Geriatr Med. 2020, 36:1-12. 10.1016\/j.cger.2019.08.002","journal-title":"Clin Geriatr Med"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.20220522","article-title":"Neurodevelopmental and neurodegenerative illnesses: Autism, Fragile X syndrome, Parkinson's disease, and dementia","volume":"179","author":"Kalin NH","year":"2022","unstructured":"Kalin NH. Neurodevelopmental and neurodegenerative illnesses: Autism, Fragile X syndrome, Parkinson's disease, and dementia. Am J Psychiatry. 2022, 179:515-8. 10.1176\/appi.ajp.20220522","journal-title":"Am J Psychiatry"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-319-71779-1_1","article-title":"Clinical features of Huntington's disease","volume":"1049","author":"Ghosh R","year":"2018","unstructured":"Ghosh R, Tabrizi SJ. Clinical features of Huntington's disease. Adv Exp Med Biol. 2018, 1049:1-28. 10.1007\/978-3-319-71779-1_1","journal-title":"Adv Exp Med Biol"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1111\/ene.13413","article-title":"Huntington's disease: a clinical review","volume":"25","author":"McColgan P","year":"2018","unstructured":"McColgan P, Tabrizi SJ. Huntington's disease: a clinical review. Eur J Neurol. 2018, 25:24-34. 10.1111\/ene.13413","journal-title":"Eur J Neurol"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.2147\/JPR.S243222","article-title":"Cancer pain management: An Italian Delphi survey from the Rational Use of Analgesics (RUA) Group","volume":"13","author":"Varrassi G","year":"2020","unstructured":"Varrassi G, De Conno F, Orsi L, Puntillo F, Sotgiu G, Zeppetella J, Zucco F. Cancer pain management: An Italian Delphi survey from the Rational Use of Analgesics (RUA) Group. J Pain Res. 2020, 13:979-86. 10.2147\/JPR.S243222","journal-title":"J Pain Res"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1016\/j.pain.2009.05.013","article-title":"Sigma-1 receptors regulate activity-induced spinal sensitization and neuropathic pain after peripheral nerve injury","volume":"145","author":"Puente B","year":"2009","unstructured":"Puente B, Nadal X, Portillo-Salido E, et al.. Sigma-1 receptors regulate activity-induced spinal sensitization and neuropathic pain after peripheral nerve injury. Pain. 2009, 145:294-303. 10.1016\/j.pain.2009.05.013","journal-title":"Pain"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(17)30084-4","article-title":"Neurological consequences of obesity","volume":"16","author":"O'Brien PD","year":"2017","unstructured":"O'Brien PD, Hinder LM, Callaghan BC, Feldman EL. Neurological consequences of obesity. Lancet Neurol. 2017, 16:465-77. 10.1016\/S1474-4422(17)30084-4","journal-title":"Lancet Neurol"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1002\/ejp.897","article-title":"Blockade of sigma 1 receptors alleviates sensory signs of diabetic neuropathy in rats","volume":"21","author":"Paniagua N","year":"2017","unstructured":"Paniagua N, Gir\u00f3n R, Goicoechea C, L\u00f3pez-Miranda V, Vela JM, Merlos M, Mart\u00edn Fontelles MI. Blockade of sigma 1 receptors alleviates sensory signs of diabetic neuropathy in rats. Eur J Pain. 2017, 21:61-72. 10.1002\/ejp.897","journal-title":"Eur J Pain"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23147572","article-title":"Sigma-1 receptor in retina: neuroprotective effects and potential mechanisms","volume":"23","author":"Xu Z","year":"2022","unstructured":"Xu Z, Lei Y, Qin H, Zhang S, Li P, Yao K. Sigma-1 receptor in retina: neuroprotective effects and potential mechanisms. Int J Mol Sci. 2022, 23:7572. 10.3390\/ijms23147572","journal-title":"Int J Mol Sci"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-319-50174-1_10","article-title":"Sigma-1 receptors and neurodegenerative diseases: Towards a hypothesis of sigma-1 receptors as amplifiers of neurodegeneration and neuroprotection","volume":"964","author":"Nguyen L","year":"2017","unstructured":"Nguyen L, Lucke-Wold BP, Mookerjee S, Kaushal N, Matsumoto RR. Sigma-1 receptors and neurodegenerative diseases: Towards a hypothesis of sigma-1 receptors as amplifiers of neurodegeneration and neuroprotection. Adv Exp Med Biol. 2017, 964:133-52. 10.1007\/978-3-319-50174-1_10","journal-title":"Adv Exp Med Biol"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2018.01369","article-title":"\u03b2-Arrestin based receptor signaling paradigms: Potential therapeutic targets for complex age-related disorders","volume":"9","author":"van Gastel J","year":"2018","unstructured":"van Gastel J, Hendrickx JO, Leysen H, Santos-Otte P, Luttrell LM, Martin B, Maudsley S. \u03b2-Arrestin based receptor signaling paradigms: Potential therapeutic targets for complex age-related disorders. Front Pharmacol. 2018, 9:1369. 10.3389\/fphar.2018.01369","journal-title":"Front Pharmacol"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1016\/j.bpa.2020.06.003","article-title":"A comprehensive review of partial opioid agonists for the treatment of chronic pain","volume":"34","author":"Gress K","year":"2020","unstructured":"Gress K, Charipova K, Jung JW, et al.. A comprehensive review of partial opioid agonists for the treatment of chronic pain. Best Pract Res Clin Anaesthesiol. 2020, 34:449-61. 10.1016\/j.bpa.2020.06.003","journal-title":"Best Pract Res Clin Anaesthesiol"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2020.1511","article-title":"Methadone for opioid use disorder-Decades of effectiveness but still miles away in the US","volume":"77","author":"Joudrey PJ","year":"2020","unstructured":"Joudrey PJ, Edelman EJ, Wang EA. Methadone for opioid use disorder-Decades of effectiveness but still miles away in the US. JAMA Psychiatry. 2020, 77:1105-6. 10.1001\/jamapsychiatry.2020.1511","journal-title":"JAMA Psychiatry"},{"key":"ref38","unstructured":"National Institute on Drug Abuse. How effective are medications to treat opioid use disorder?. (December 3, 2021). Accessed. July 25, 2023: https:\/\/nida.nih.gov\/publications\/research-reports\/medications-to-treat-opioid-addiction\/efficacy-medications-opioid-...."},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.166.12.1280","article-title":"Drug-induced long QT syndrome in injection drug users receiving methadone: high frequency in hospitalized patients and risk factors","volume":"166","author":"Ehret GB","year":"2006","unstructured":"Ehret GB, Voide C, Gex-Fabry M, et al.. Drug-induced long QT syndrome in injection drug users receiving methadone: high frequency in hospitalized patients and risk factors. Arch Intern Med. 2006, 166:1280-7. 10.1001\/archinte.166.12.1280","journal-title":"Arch Intern Med"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpain.2014.01.495","article-title":"Methadone overdose and cardiac arrhythmia potential: findings from a review of the evidence for an American Pain Society and College on Problems of Drug Dependence clinical practice guideline","volume":"15","author":"Chou R","year":"2014","unstructured":"Chou R, Weimer MB, Dana T. Methadone overdose and cardiac arrhythmia potential: findings from a review of the evidence for an American Pain Society and College on Problems of Drug Dependence clinical practice guideline. J Pain. 2014, 15:338-65. 10.1016\/j.jpain.2014.01.495","journal-title":"J Pain"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.15123","article-title":"The end of the X-waiver: not a moment too soon!","volume":"13","author":"Pergolizzi J","year":"2021","unstructured":"Pergolizzi J, LeQuang JA, Breve F. The end of the X-waiver: not a moment too soon!. Cureus. 2021, 13:e15123. 10.7759\/cureus.15123","journal-title":"Cureus"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD002207.pub4","article-title":"Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence","author":"Mattick RP","year":"2014","unstructured":"Mattick RP, Breen C, Kimber J, Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev. 2014, CD002207. 10.1002\/14651858.CD002207.pub4","journal-title":"Cochrane Database Syst Rev"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-020-00743-3","article-title":"Methadone for pain management: A pharmacotherapeutic review","volume":"34","author":"Kreutzwiser D","year":"2020","unstructured":"Kreutzwiser D, Tawfic QA. Methadone for pain management: A pharmacotherapeutic review. CNS Drugs. 2020, 34:827-39. 10.1007\/s40263-020-00743-3","journal-title":"CNS Drugs"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1111\/jcpt.12196","article-title":"The clinical analgesic efficacy of buprenorphine","volume":"39","author":"Raffa RB","year":"2014","unstructured":"Raffa RB, Haidery M, Huang HM, et al.. The clinical analgesic efficacy of buprenorphine. J Clin Pharm Ther. 2014, 39:577-83. 10.1111\/jcpt.12196","journal-title":"J Clin Pharm Ther"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1111\/j.1533-2500.2010.00378.x","article-title":"Current knowledge of buprenorphine and its unique pharmacological profile","volume":"10","author":"Pergolizzi J","year":"2010","unstructured":"Pergolizzi J, Aloisi AM, Dahan A, et al.. Current knowledge of buprenorphine and its unique pharmacological profile. Pain Pract. 2010, 10:428-50. 10.1111\/j.1533-2500.2010.00378.x","journal-title":"Pain Pract"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1213\/ANE.0000000000003365","article-title":"Dezocine alleviates morphine-induced dependence in rats","volume":"128","author":"Wu FX","year":"2019","unstructured":"Wu FX, Babazada H, Gao H, et al.. Dezocine alleviates morphine-induced dependence in rats. Anesth Analg. 2019, 128:1328-35. 10.1213\/ANE.0000000000003365","journal-title":"Anesth Analg"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/162611-the-emerging-role-of-sigma-receptors-in-pain-medicine","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T20:02:10Z","timestamp":1707508930000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/162611-the-emerging-role-of-sigma-receptors-in-pain-medicine"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,28]]},"references-count":46,"URL":"https:\/\/doi.org\/10.7759\/cureus.42626","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7,28]]}}}